Monday, June 20, 2022 12:39:17 PM
No, because it never happened. You have been corrected on this already, so you know it is false. Repeating a false fact 100 times does not make it right.
Is still question if we will even see proper TLD (which we have not), but that is not my primary argument. Never was.
Since you have a hard time remembering my core argument, let me say it once again.
. In the time period from 7-4 years NWBO conducted several efficacy analysis with the stats team unblinded while NWBO and investigators remain blinded.
. Both PFS and OS analysis failed.
. NWBO waiting on an OS tail. That failed.
. Still blinded, NWBO resorted to the ECA endpoints.
And if so, no RA will accept that change as being valid
I know the replies will be that this is wild speculation, but there is plenty of basis in known facts.
. The trial called for several unblinded efficacy analysis for PF and OS in that timeframe.
. NWBO said they would happen, and NWBO said that even though stat team would be unblinded, NWBO and trial would remain blinded.
. NWBO never said they did not happen.
. If they did not happen then it was a change in the trial protocol that was legally required to be posted. And that did not happen.
I will call that a huge preponderance of evidence pointing to analysis would happen. And we know if they did happen, they failed. Nobody can submit any evidence to suggest they did not happen.
And before bio replies, no Court every ruled on this issue.
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM